DARA CEO Says Firm Intends To Investigate Point’s Talabostat For Leukemia, Melanoma After Reverse Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Point Therapeutics' DPP-4 inhibitor, on clinical hold for non-small cell lung cancer, still "has possibilities in chronic lymphocytic leukemia and ... melanoma," DARA BioSciences CEO Richard Franco tells "The Pink Sheet" DAILY.